公开(公告)号：US20240082437A1

公开(公告)日：2024-03-14

申请号：US18271835

申请日：2022-01-10

Applicant: Hoffmann-La Roche Inc.

Inventor： Christian KLEIN ,  Alexander HAAS ,  Sabine IMHOF-JUNG ,  Sofia FROST

IPC: A61K51/10 ,  A61P35/00 ,  C07K16/30

CPC classification number: A61K51/1048 ,  A61P35/00 ,  C07K16/3007

Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target effector moieties to said cells, and to methods of using the same.

公开(公告)号：US20240173442A1

公开(公告)日：2024-05-30

申请号：US18271928

申请日：2022-01-11

Applicant: Hoffmann-La Roche Inc.

Inventor： Sara COLOMBETTI ,  Sofia FROST

IPC: A61K51/10 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K51/1048 ,  A61K39/3955 ,  A61K51/1096 ,  A61P35/00

Abstract: The present invention relates to combination therapies including the use of pre-targeted radioimmunotherapy (PRIT).

公开(公告)号：US20220267463A1

公开(公告)日：2022-08-25

申请号：US17625719

申请日：2020-07-10

Applicant: Hoffmann-La Roche Inc.

Inventor： Pablo UMANA ,  Sabine IMHOF-JUNG ,  Alexander HAAS ,  Christian KLEIN ,  Sofia FROST ,  Felix BORMANN ,  Guy GEORGES ,  Sebastian FENN ,  Florian LIPSMEIER ,  Daniela MATSCHEKO ,  Joerg MOELLEKEN ,  Barbara WEISER

IPC: C07K16/30 ,  C07K16/44 ,  A61K51/04 ,  A61P35/00

Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.

公开(公告)号：US20230272116A1

公开(公告)日：2023-08-31

申请号：US18014729

申请日：2021-07-08

Applicant: Hoffmann-La Roche Inc.

Inventor： Alexander HAAS ,  Sabine IMHOF-JUNG ,  Christian KLEIN ,  Sofia FROST

IPC: C07K16/46 ,  A61K51/04

CPC classification number: C07K16/468 ,  A61K51/0482 ,  A61K51/0495 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/565

Abstract: The present invention relates to a set of antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same. The antibodies each comprising a Fab binding to the target antigen fused at the C-terminus of the VH to the N-terminus of the Fc and a VH or VL binding to a radiolabelled compound. The VH or VL are fused at the C-terminus to the N-terminus of the Fc. VH and VL form an antigen binding site when the antibody binds via the scFv to the target antigen.

公开(公告)号：US20220031871A1

公开(公告)日：2022-02-03

申请号：US17048072

申请日：2019-04-16

Applicant: Hoffmann-La Roche Inc. ,  Orano Med SAS

Inventor： Julien TORGUE ,  Paul JUREK ,  Federico ROJAS-QUIJANO ,  Garry E. KIEFER ,  Olivier FREYTAG ,  Christian GERDES ,  Christian KLEIN ,  Pablo UMANA ,  Alexander HAAS ,  Sofia FROST ,  Amal SAIDI ,  Tapan NAYAK

IPC: A61K51/04 ,  A61K51/06 ,  A61K51/10 ,  A61P35/00

Abstract: The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies, It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and useful in such methods.